Insmed, Inc. $INSM Shares Bought by Driehaus Capital Management LLC

Key Points

• Driehaus Capital Management LLC increased its stake in Insmed, Inc. by 93.5% during the first quarter, owning approximately $25.28 million worth of shares.
• Several analysts have raised their price targets for Insmed, with an average price target now at $132.57 and a consensus rating of Moderate Buy.
• Insmed reported a loss per share of ($1.70) for the last quarter, missing analysts’ estimates, although revenue increased 18.9% year-over-year to $107.42 million.

Driehaus Capital Management LLC lifted its holdings in Insmed, Inc. (NASDAQ:INSM - Free Report) by 93.5% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 331,459 shares of the biopharmaceutical company's stock after buying an additional 160,170 shares during the period. Driehaus Capital Management LLC owned approximately 0.18% of Insmed worth $25,287,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently bought and sold shares of INSM. Cullen Frost Bankers Inc. raised its stake in Insmed by 164.9% during the first quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 221 shares during the period. Elequin Capital LP purchased a new position in Insmed during the fourth quarter worth about $28,000. NBC Securities Inc. purchased a new position in Insmed during the first quarter worth about $49,000. Versant Capital Management Inc raised its stake in Insmed by 546.3% during the first quarter. Versant Capital Management Inc now owns 698 shares of the biopharmaceutical company's stock worth $53,000 after purchasing an additional 590 shares during the period. Finally, Signaturefd LLC raised its stake in Insmed by 60.0% during the first quarter. Signaturefd LLC now owns 867 shares of the biopharmaceutical company's stock worth $66,000 after purchasing an additional 325 shares during the period.

Insmed Stock Down 0.7%

Shares of INSM stock traded down $0.97 during trading on Thursday, reaching $142.53. The company's stock had a trading volume of 2,012,737 shares, compared to its average volume of 2,980,265. The company has a debt-to-equity ratio of 0.45, a current ratio of 6.68 and a quick ratio of 6.33. The company has a market capitalization of $30.13 billion, a price-to-earnings ratio of -24.96 and a beta of 0.97. The stock's 50-day moving average price is $113.72 and its 200 day moving average price is $89.22. Insmed, Inc. has a 1-year low of $60.40 and a 1-year high of $146.84.

Insmed (NASDAQ:INSM - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported ($1.70) earnings per share for the quarter, missing analysts' consensus estimates of ($1.30) by ($0.40). The business had revenue of $107.42 million during the quarter, compared to analyst estimates of $104.06 million. Insmed had a negative net margin of 259.82% and a negative return on equity of 195.37%. The company's revenue for the quarter was up 18.9% on a year-over-year basis. During the same quarter last year, the firm posted ($1.94) EPS. Insmed has set its FY 2025 guidance at EPS. On average, research analysts anticipate that Insmed, Inc. will post -4.56 EPS for the current year.

Insider Activity at Insmed

In other Insmed news, COO Roger Adsett sold 25,000 shares of the business's stock in a transaction that occurred on Tuesday, August 19th. The shares were sold at an average price of $127.58, for a total transaction of $3,189,500.00. Following the completion of the transaction, the chief operating officer owned 105,637 shares in the company, valued at $13,477,168.46. The trade was a 19.14% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Orlov S. Nicole Schaeffer sold 99,172 shares of the business's stock in a transaction that occurred on Wednesday, June 11th. The stock was sold at an average price of $93.42, for a total transaction of $9,264,648.24. Following the transaction, the insider owned 89,407 shares of the company's stock, valued at $8,352,401.94. This trade represents a 52.59% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 535,320 shares of company stock worth $54,581,793 over the last ninety days. 3.00% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on INSM shares. Bank of America lifted their target price on shares of Insmed from $94.00 to $109.00 and gave the stock a "buy" rating in a research note on Wednesday, June 11th. UBS Group lifted their target price on shares of Insmed from $124.00 to $133.00 and gave the stock a "buy" rating in a research note on Friday, August 8th. HC Wainwright lifted their target price on shares of Insmed from $90.00 to $120.00 and gave the stock a "buy" rating in a research note on Wednesday, June 11th. Royal Bank Of Canada lifted their price target on shares of Insmed from $108.00 to $120.00 and gave the company an "outperform" rating in a research report on Friday, August 8th. Finally, Citigroup upgraded shares of Insmed to a "buy" rating in a research report on Tuesday, June 10th. Sixteen investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $134.79.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.